Loading clinical trials...
Loading clinical trials...
A Multi-centre, Open-label, Single-group Exploratory Trial of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy
Conditions
Interventions
Sparsentan
Locations
5
United Kingdom
Cambridge University Hospitals NHS Trust
Cambridge, England, United Kingdom
Northern Care Alliance NHS Foundation Trust - Salford Royal
Salford, England, United Kingdom
Royal Infirmary of Edinburgh & Western General Hospital
Edinburgh, Scotland, United Kingdom
University Hospital of wales
Cardiff, Wales, United Kingdom
Leicester General Hospital, University Hospitals of Leicester NHS Trust
Leicester, United Kingdom
Start Date
December 10, 2020
Primary Completion Date
March 31, 2025
Completion Date
March 31, 2025
Last Updated
January 6, 2025
NCT07355296
NCT07375758
NCT06337838
NCT05318196
NCT06291376
NCT05728216
Lead Sponsor
University of Leicester
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions